Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility & Risk

Talaris Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Insider and Institutional Ownership

65.4% of Talaris Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 16.6% of Talaris Therapeutics shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Talaris Therapeutics and Genocea Biosciences, as reported by MarketBeat.

Talaris Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 584.21%.

Valuation and Earnings

This table compares Talaris Therapeutics and Genocea Biosciences' gross revenue, earnings per share (EPS) and valuation.

Genocea Biosciences has higher revenue and earnings than Talaris Therapeutics. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Talaris Therapeutics and Genocea Biosciences' net margins, return on equity and return on assets.

Summary

Genocea Biosciences beats Talaris Therapeutics on 6 of the 10 factors compared between the two stocks.

About Talaris Therapeutics

(Get Rating)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.